The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Subscribe To Our Newsletter & Stay Updated
